Roche (Piramed) PI3K inhbitor PI-103 enhances tumor radiosensitivity

Piramed’s PI3K inhibitor PI103 has been shown to reduce phosphorylation of AKT at serine 473 leading to enhanced efficacy in radiotherapy

Erbitux approved in Japan for Advanced Colorectal Cancer

ImClone Systems have announced that Erbitux (cetuximab) has been approved in Japan for use in treating patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or recurrent CRC, and allows the use of ERBITUX plus irinotecan in second and further lines of mCRC. With this approval, ERBITUX is the first ever EGFR-targeted monoclonal [...]